14th Annual BIO CEO & Investor Conference Introduces Fireside Chats with Industry Leaders

Fireside Chats to focus on biopharma R&D and corporate strategy.

WASHINGTON, D.C. (January 18, 2012) –The Biotechnology Industry Organization (BIO) today announced the addition of Fireside Chats with senior industry executives to this year’s BIO CEO & Investor Conference. The chats will feature a set of moderated, one-on-one conversations with pharma R&D chiefs and industry leaders, followed by an interactive question and answer session.  This format will allow attendees to hear industry leaders provide insight into biopharma R&D and strategy. The event, to be held February 13-14, 2012 in New York City, is the largest independent investor conference focused on established and publicly-traded biotechnology companies.

“The biopharmaceutical industry is undergoing a dramatic transformation to meet the growing demand for treatments and cures and overcome a challenging financial environment,” said Moncef Slaoui, PhD, Chairman, Research & Development, GlaxoSmithKline plc. “The Fireside Chats will offer an ideal atmosphere to engage in thought-provoking discussions that will address these timely issues facing our industry.”

Fireside Chat participants include:

  • Moncef Slaoui, PhD, Chairman, Research & Development, GlaxoSmithKline plc

Dr. Slaoui became Chairman, Research & Development in June 2006. He is a member of the Board and the Corporate Executive Team.  Dr. Slaouiha has overall responsibility for all Pharma and Vaccine R&D activities and overall responsibility for global Oncology and Vaccine businesses.

Monday, February 13th, 8:00 – 8:45 a.m.


  • Mikael Dolsten, MD, PhD, President, Worldwide Research & Development, Pfizer Inc.

Mr. Dolsten is the President of Worldwide Research and Development. He is also co-chair of the company’s Portfolio Strategy and Investment (PSI) Committee, which governs major pipeline investments and strategic R&D priorities.

Tuesday, February 14th, 8:00 – 8:45 a.m.


  • John Milligan, PhD, President & Chief Operating Officer, Gilead Sciences

Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.

Tuesday, February 14th, 2:30 – 2:55 p.m.

In addition to Fireside Chats, the conference will host Therapeutic Workshops, Business Roundtables and BIO One-on-One Partnering. The Therapeutic Workshops will address topics such as oncology, companion diagnostics, neurological and cardiovascular diseases while the Business Roundtables will focus on biotech drug launches, unique business models and licensing and deal making. BIO’s One-on-One Partnering system provides the opportunity to arrange meetings between investors, companies and industry executives. Furthermore, the event features presentations from more than 130 leading biotechnology and pharmaceutical companies.

Qualified institutional and venture investors whose primary activity is direct investment in research and development companies are eligible for complimentary registration.  Equity research analysts from investment banking institutions also qualify as investors.  Media registrationis complimentary for credentialed members of the media.All registrations are subject to verification of credentials.

BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors.  The bank sponsors include: BMO Capital Market, Lazard, Leerink Swann, Rodman & Renshaw, LLC and Roth Capital Partners.

To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit here